It is well known that MR data contains detailed information with high tissue contrast and that PET imaging gives molecular/biochemical information with high molecular sensitivity but what is the added value? A major goal with treatment planning is to delineate the tumor volume, which can be done with both MR and PET, but since the both modalities show different characteristics of the tumor the volume might differ between them. Challenges from the imaging point of view will be discussed. The availability to PET/CT is much higher and the challenges with this method are fewer. Some comparison of the two hybrid modalities will be done. The majority of PET studies are done with the tracer fluorodexyglucose, FDG, but beyond FDG a large number of tracer are available, all giving information about different biochemical properties of the tumor. A few of these tracers will be presented and discussed. Methods: Hybrid PET/MR imaging offers the possibility to combine molecular information from PET with high resolution anatomical MR imaging. Consequently, a combination of the two different imaging data sets seems promising for improved automatic target volume delineation (TVD). An automatic cosegmentation algorithm has been developed in our institution which derives probabilities of tumor presence by combining PET and MR data. Finally, the PET/MR-based probability maps are segmented to generate RT target volumes. Automatically segmented target volumes were compared to manual delineations from three experienced radiation oncologists. Furthermore, combined PET/MR imaging allows to assess PET and functional MR data at the same time. In the context of a clinical study, diffusion weighted (DW) as well as dynamic contrast enhanced (DCE) MRI were acquired in addition to anatomical images as well as FMISO and FDG PET images. Pairwise correlations of the different functional parameters were calculated in order to analyze for redundancy or complementarity respectively.
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Results: Automatic co-segmentation of tumor volumes based on combined FDG PET/MR imaging in head and neck cancer revealed robust and reproducible contours. The comparison of automatic and manual target volumes showed good agreement in terms of volume overlap. Deviation of the automatic compared to the manual contours was in the same order of magnitude as inter-observer variation. Compared to PET-based TVD, additional information from high resolution MR data improves automatic segmentation. A pairwise correlation analysis of parameters derived from FMISO PET, FDG PET, DW-and DCE-MRI on a voxel-level did only show moderate to low correlation coefficients hinting at a complementarity of the different investigated imaging methods. However, large inter-patient variations in terms of pairwise parameter correlations were observed.
Conclusion:
Functional and molecular imaging with combined PET/MR has the potential to improve TVD. At the same time, PET/MR allows to assess different levels of biological information which may in the future be important to derive individualized measures of radiation sensitivity. As a consequence, PET/MR imaging opens new doors for personalized RT planning and delivery in the near future. Imaging is fundamentally important in modern radiotherapy. For several of the most common diagnoses both PET and MR provide important information in the clinical decision making at the radiotherapy department. The combination of PET and MR in integrated PET/MR scanners could be the most efficient imaging modality for these patients. PET/MR has however primarily been designed for diagnostics and adjustments are needed to enable effective use in radiotherapy. This includes for example the ability to image the patient in treatment position, the ability to account for immobilization devices in the attenuation correction, and the development of adequate quality assurance methods. Results: In 14 patients, the median interval between the scans was 4.5 +/-2.1 days (range: 2-7days). Seven patients (50%) exhibited hypoxia (HX-4 TBR>1.4) in the primary tumour and 4 of 10 patients (40%) had nodal disease with an HX4 TBR>1.4 in the lymph nodes. In total 9/14 patients (64%) showed hypoxia at baseline in the primary tumour and/or the lymph nodes. The effect of nitroglycerin on HX-4 uptake in hypoxic lesions was as follows: in 8/11 volumes (72%) and in 6/9 patients (66%) nitroglycerin administration resulted in a decrease of the TBR of HX-4. Also, the median HF decreased from 12.9% to 1.2% (p=0.029), corresponding to a decrease in the median hypoxic volume of 5.4 cc to 0.5 cc (p=0.033). In the 7 non-hypoxic tumours and 6 non-hypoxic nodal volumes present at baseline, nitroglycerin caused a decrease of the TBR of HX-4 in 5, an increase in 5 and no effect in 3 lesions. None of the non-hypoxic lesions became hypoxic (TBR >1.4) after administration of nitroglycerin. 
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Conclusion:
Nitroglycerin causes a significant decrease in the hypoxic fraction and hypoxic volume of a majority of hypoxic non-small cell lung cancer tumours and metastatic lymph nodes. This promising result encourages further investigation of nitroglycerin as a sensitizing agent in a selected population. CT-based perfusion studies and lab experiments (data not shown) suggest this effect is mediated by an inhibition of mitochondrial respiration rather than a vascular effect.
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Biomarker-based hypoxia-adapted radiochemotherapy: preclinical study in HPV+/-H&N cancer xenografts L. Koi In a randomized clinical trial Nimorazole improved LC and survival of patients with HNSCC treated with RT. Biomarker studies using tumour material from this trial indicate that hypoxic tumours predominantly benefit from nimorazole, supporting a predictive value for hypoxia assessment. However, this has not been prospectively evaluated for radiochemotherapy (RCTx) which represents the current standard of care in locally advanced head and neck cancer. The hypothesis of the ongoing study is that the microenvironmental parameters are also predictive for response to hypoxic cell sensitizing with nimorazole in combination with RCTx.
Material and Methods:
We studied 8 different human HPVnegative and -positive HNSCC in a nude mice xenograft model. Irradiation was performed with 30 fractions (fx) in six weeks combined with weekly cisplatin (3 mg/kg i. p.). Nimorazole (0.3 mg/g i. p.) was applied before each irradiation and was started with the first fx or after 10 fx. Effect of nimorazole was quantified as LC 120/180 days after irradiation. For histological evaluation tumours were excised unirradiated or after 10 fx with and without nimorazole. Using quantitative image analysis, microenvironmental parameter such pimonidazole hypoxic volume (pHV), relative vascular area (RVA) and perfused fraction of vessels (PF) were determined.
Results:
The data of the cell lines show pronounced heterogeneity in the effect of nimorazole on local tumour control after fractionated radiochemotherapy. Nimorazole significantly improved local tumour control in four of the eight tumours. In the two responder models FaDu and SAS, nimorazole was equally effective when given from start of radiochemotherapy or after 10 fx. The treatment with both, RCTx and the application of nimorazole and cisplatin were well tolerated by the animals. Furthermore, pHV was significantly reduced after 10 fx RCT with and without nimorazole in all four responder models in contrast to the non-responders.
Conclusion:
Apparently, the decrease of pHV after the first fractions of RCTx has potential as a predictive biomarker for LC for combination of RCTx with nimorazole and should therefore be further evaluated in experimental FMISO analysis and also in clinical trials using hypoxic cell radiosensitisation during RCTx. Purpose or Objective: There is increasing interest in defining a functional association between miRNAs, endogenous small non-coding RNA molecules that negatively regulate gene expression, and tumor radiation response, with the aim of rationally designing miRNA-based strategies to increase patient radiosensitivity. In this study, we investigated for the first time the ability of miR-875-5p, a miRNA the role of which in human cancer has not been so far investigated, to enhance the radiation response of prostate cancer (PCa) cells.
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Material and Methods:
The search for miR-875-5p targets relevant to radiation response was carried out by prediction algorithms and confirmed by the luciferase assay. miR-875-5p reconstitution by miRNA mimics in PCa cell lines (DU145 and PC-3) was used to elucidate its biological role. Radiation response in miRNA-reconstituted and control cells was assessed by clonogenic assay, immunofluorescence-based detection of nuclear γ-H2AX foci and single-cell electrophoresis comet assay.
Results: EGFR was predicted by 6 different algorithms and confirmed by luciferase assay as a direct target of miR-875-5p. Given the role of EGFR in determining tumor cell resistance to ionizing radiation by promoting epithelial-tomesenchymal transition (EMT) and enhancing DNA-dependent protein kinase activity and DNA damage repair, we assessed whether miR-875-5p reconstitution in PCa cells was able to counteract EGFR-mediated radio-resistance. Indeed, miRNA ectopic expression significantly increased the sensitivity of both DU145 and PC-3 cell lines to radiation, as indicated by the reduced clonogenic cell survival. Consistently, the kinetics of accumulation and repair of γ-H2AX nuclear foci showed that the resolution of foci was significantly slower in miR-875-5p reconstituted cells compared to control cells. In addition, when a more direct assessment of radiation-induced DNA damage and repair at the single cell level was performed by the comet assay, DNA comet tail moments were found to be significantly extended in miR-875-5p reconstituted cells compared to control cells, confirming the ability of the miRNA to impair DNA repair processes. Ectopic expression of miR-875-5p in PCa cells was also able to counteract EMT as indicated by changes in cell morphology, marked cytoskeleton architecture rearrangements, reduced migration ability and increased mRNA and protein levels of E-cadherin and β-catenin, the two most important molecular players in the EMT process.
Conclusion:
Overall, results from this study support the clinical interest in developing a novel therapeutic approach for PCa based on miR-875-5p reconstitution to increase response to radiotherapy.
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FoxO proteins and non-functional p53 determine stemness and radiosensitivity of GBM-stem cells E. Firat 
